预约演示

更新于：2025-05-07

NCC

更新于：2025-05-07

基本信息

别名

Na-Cl cotransporter、Na-Cl symporter、NCC

+ [7]

简介

Electroneutral sodium and chloride ion cotransporter, which acts as a key mediator of sodium and chloride reabsorption in kidney distal convoluted tubules (PubMed:18270262, PubMed:21613606, PubMed:22009145, PubMed:36351028, PubMed:36792826). Also acts as a receptor for the pro-inflammatory cytokine IL18, thereby contributing to IL18-induced cytokine production, including IFNG, IL6, IL18 and CCL2 (By similarity). May act either independently of IL18R1, or in a complex with IL18R1 (By similarity).

关联

103

苯磺酸氨氯地平/氯噻酮/替米沙坦

靶点

AT1R x NCC x VDCCs

作用机制

AT1R拮抗剂 [+2]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

韩国

首次获批日期2019-08-23

Amlodipine Besylate/Irbesartan/Hydrochlorothiazide

苯磺酸氨氯地平/厄贝沙坦/氢氯噻嗪

靶点

AT1R x NCC x VDCCs

作用机制

AT1R拮抗剂 [+2]

在研机构

WinMedica

原研机构

WinMedica

在研适应症

高血压

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

捷克 [+1]

首次获批日期2019-02-18

Atorvastatin/Hydrochlorothiazide/Aspirin/Enalapril

阿托伐他汀/氢氯噻嗪/阿司匹林/依那普利

靶点

ACE x COXs x HMGCR x NCC

作用机制

ACE抑制剂 [+3]

在研机构

Alborz Darou Pharmaceutical Co.

原研机构

Alborz Darou Pharmaceutical Co.

在研适应症

心血管疾病

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

伊朗

首次获批日期2018-02-01

821

项与 NCC 相关的临床试验

NCT05963568

/ Not yet recruiting临床3期IIT

Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)

The overall objective of the Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment II (SMAART-II) is to deploy a hybrid study design to firstly, demonstrate the efficacy of a polypill (Polycap ®) containing fixed doses of antihypertensives, a statin, and antiplatelet therapy taken as two capsules, once daily orally in reducing composite vascular risk over 24 months vs. usual care among 500 recent stroke patients encountered at 12 hospitals in Ghana. Secondly, SMAART II seeks to develop an implementation strategy for routine integration and policy adoption of this polypill for post-stroke cardiovascular risk reduction in an under-resourced system burdened by suboptimal care and outcomes.

开始日期2025-06-01

申办/合作机构

Northern California Institute for Research & Education

CTR20251066

/ RecruitingN/A

坎地沙坦酯氢氯噻嗪片（Ⅱ）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验。

以药代动力学参数为终点指标，比较空腹和高脂餐后给药条件下，合肥合源药业有限公司生产的坎地沙坦酯氢氯噻嗪片（Ⅱ）与CHEPLAPHARM Arzneimittel GmbH持证的坎地沙坦酯氢氯噻嗪片（Ⅱ）在健康成年人群中吸收程度和速度的差异，对两制剂的生物等效性进行评价。次要目的：评价健康受试者在空腹和高脂餐后给药条件下口服受试制剂坎地沙坦酯氢氯噻嗪片（Ⅱ）和参比制剂坎地沙坦酯氢氯噻嗪片（Ⅱ）的安全性。

开始日期2025-04-16

申办/合作机构

合肥合源药业有限公司

CTR20250503

/ CompletedN/A

吲达帕胺缓释片在健康受试者中的随机、开放、两周期、双交叉空腹及餐后生物等效性预试验

主要目的：考察空腹及餐后条件下，初步评价吉林天衡英睿制药有限公司研制的吲达帕胺缓释片（规格：1.5mg）与施维雅(天津)制药有限公司持证的吲达帕胺缓释片（商品名：纳催离，规格：1.5mg）在中国健康受试者中的人体生物等效性，为正式试验的方案设计提供依据。次要目的：评价吲达帕胺缓释片受试制剂和参比制剂在健康受试者中的安全性。

开始日期2025-02-28

申办/合作机构

吉林天衡英睿制药有限公司

100 项与 NCC 相关的临床结果

登录后查看更多信息

100 项与 NCC 相关的转化医学

登录后查看更多信息

0 项与 NCC 相关的专利（医药）

登录后查看更多信息

2,060

项与 NCC 相关的文献（医药）

2025-04-26·Japanese Journal of Clinical Oncology

A case of Li–Fraumeni syndrome caused by a 3.6 kb deletion in the TP53 gene suggested by additional data from the NCC Oncopanel

Article

作者: Shirota, Hidekazu ; Ogawa, Maki ; Yasuda, Jun ; Asano, Naoki ; Takeuchi, Mika ; Fujimori, Haruna ; Ito, Shin ; Souma, Satoshi ; Yamaguchi, Kazunori ; Otsuka, Kazunori ; Ohnuki, Koji

AbstractA Japanese woman with Li–Fraumeni syndrome in her 40s underwent comprehensive genetic profiling accompanied by germline data using the Oncoguide NCC Oncopanel, but no germline pathogenic variants in the tumor suppressor gene TP53 were detected. However, careful examination of additional data in the report suggested the presence of a large TP53 deletion. Custom targeting next-generation sequencing and nanopore sequencing revealed a 3.6 kb deletion located between intron 1 and intron 6 of TP53. This finding indicates that the NCC Oncopanel is suggestive for detecting large germline deletions in tumor suppressor genes.

2025-04-01·Fish & Shellfish Immunology

Functional study of tilapia T cell activation stimulus signal molecule CD2

Article

作者: Li, Yuan ; Lu, Yi-Shan ; Wang, Zhi-Wen ; Wang, Bei

As a co-stimulatory signaling molecule, CD2 provides a secondary stimulatory signal during T-cell activation. Research on CD2 in lower vertebrates remains limited. In this article, we identify the tilapia CD2 gene (GenBank accession number: OM974656; designated as OnCD2), which is predominantly expressed in various immune tissues of tilapia. Additionally, we determine the interaction between tilapia CD2 and its ligand, CD48. Using the magnetic bead method, we identified the CD2-positive lymphocyte population in tilapia, which primarily includes Th, NCC, and B cells. Under different stimuli, the proportion of CD2-positive cells in the head kidney, peripheral blood, and spleen lymphocytes exhibited varying degrees of increase. Incubation of tilapia lymphocytes with CD2 antibody and CD48 recombinant protein upregulated the expression of genes associated with T cell activation. The results of this study demonstrate that tilapia CD2 not only plays a role in T cell activation through its interaction with the ligand CD48, but also mediates a more complex immune regulation pathway in tilapia. This research serves as a reference for the classification of fish immune cells and enhances our understanding of T cell immunity in fish.

2025-03-18·Proceedings of the National Academy of Sciences

Cell extrusion drives neural crest cell delamination

Article

作者: Moore Zajic, Emma L. ; Zhao, Ruonan ; Wood, Christopher ; Yi, Kexi ; Trainor, Paul A. ; McKinney, Mary C.

Neural crest cells (NCC) comprise a heterogeneous population of cells with variable potency that contribute to nearly every tissue and organ throughout the body. Considered unique to vertebrates, NCC are transiently generated within the dorsolateral region of the neural plate or neural tube during neurulation. Their delamination and migration are crucial for embryo development as NCC differentiation is influenced by their final resting locations. Previous work in avian and aquatic species revealed that NCC delaminate via an epithelial–mesenchymal transition (EMT), which transforms these progenitor cells from static polarized epithelial cells into migratory mesenchymal cells with fluid front and back polarity. However, the cellular and molecular mechanisms facilitating NCC delamination in mammals are poorly understood. Through time-lapse imaging of NCC delamination in mouse embryos, we identified a subset of cells that exit the neuroepithelium as isolated round cells, which then halt for a short period prior to acquiring the mesenchymal migratory morphology classically associated with delaminating NCC. High-magnification imaging and protein localization analyses of the cytoskeleton, together with measurements of pressure and tension of delaminating NCC and neighboring neuroepithelial cells, revealed that round NCC are extruded from the neuroepithelium prior to completion of EMT. Furthermore, cranial NCC are extruded through activation of the mechanosensitive ion channel, PIEZO1. Our results support a model in which cell density, pressure, and tension in the neuroepithelium result in activation of the live cell extrusion pathway and delamination of a subpopulation of NCC in parallel with EMT, which has implications for cell delamination in development and disease.

项与 NCC 相关的新闻（医药）

2023-08-17

·赛柏蓝

经典复方降压药，诚招代理

01起始联合已成为降压治疗的主要趋势2023年版ESH高血压管理指南（以下简称2023 ESH指南）已于6月下旬在第32届欧洲高血压和心血管保护会议（ESH 2023）上重磅发布。这是继2018版ESC/ESH指南后，时隔五年欧洲高血压指南的再次更新。新版指南全面总结了高血压管理各方面的最佳现有证据，在高血压的病理生理基础、血压测量、靶器官损害及心血管风险评估、启动降压药物治疗时机、降压目标值、药物治疗流程及推荐药物等方面均进行了更新和充实。其中，比较关键的一点是，在药物治疗方面2023 ESH指南再次强调了起始联合的重要性。指南认为，改善血压控制的最有效的循证治疗策略是建议大多数患者进行初始联合治疗（仅一些特殊状态可考虑单药治疗），尤其是针对血压目标值相对较低的情况；与单药治疗相比，初始联合治疗绕过了惯性单药治疗的问题，提高了患者服药依从性及长期血压达标率，并减少了相关心血管事件的发生。02临床主要的优选联合方案是哪些？我国当前临床主要推荐应用的优化联合治疗方案是：ACEI/ARB+噻嗪类利尿剂ARB+利尿剂的联合治疗禁忌症较少，安全性高，适用于大多数高血压患者的起始治疗，是各国高血压指南一致推荐的优选联合方案。以苏州中化药品的替米沙坦氢氯噻嗪片（商品名：文乐宁®）为例，替米沙坦和氢氯噻嗪合用具有协同作用，有利于改善降压效果；替米沙坦可使血钾水平略有上升，能拮抗氢氯噻嗪长期应用所致的低血钾等不良反应；氢氯噻嗪又能减少替米沙坦扩血管时由于肾脏压力利钠机制而引起的水钠潴留。ACEI/ARB+二氢吡啶类CCBCCB具有直接扩张动脉的作用，ACEI/ARB 既扩张动脉、又扩张静脉，故两药合用有协同降压作用。另外二氢吡啶类 CCB 常见的踝部水肿不良反应也可被ACEI/ARB抵消/减轻。代表品有替米沙坦氨氯地平等。二氢吡啶类CCB+噻嗪类利尿剂FEVER研究证实，二氢吡啶类CCB+噻嗪类利尿剂治疗，可降低高血压患者脑卒中发生的风险。二氢吡啶类 CCB+β受体阻滞剂CCB具有扩张血管和轻度增加心率的作用，恰好抵消β 受体阻滞剂的缩血管及减慢心率的作用,两药联合可使不良反应减轻。除以上四种组合外，其他还有一些属于可考虑使用的联合方案、不常规推荐但必要时可慎用的联合方案，应根据个体化降压治疗的基本原则，依据患者年龄、体重、高血压分级和并发症情况等，选择适合患者的最优联合方案。03在治疗的任何阶段都应优先使用SPC单片复方制剂（Single-Pill Combination，SPC）是常用的一类高血压联合治疗药物，通常由不同作用机制的两种或两种以上的降压药组成。跟传统两药单独联用（吃两种药）的方案相比，SPC具有“强化、简化、优化”的特点，其降压幅度更高、患者依从性更好，不良反应更小，能够有效提升血压达标率，得到了各版高血压指南的一致优先推荐。2023 ESH指南指出在任何治疗步骤中都应优先使用SPC，无论是在双药联合治疗开始时或任何其他治疗阶段；SPC可通过减少患者服药次数来提高患者依从性，并进一步提升血压控制的速度、效率和可预测性。04ARB+D的SPC适用于哪种类型的高血压？ARB+利尿剂的SPC禁忌症较少，安全性高，适用于大多数高血压患者的起始治疗，是各国高血压指南一致推荐的优选联合方案。2023 ESH指南如无禁忌症应优先使用RAAS抑制剂（ACEI/ARB），并将其作为一般联合的基础成分；两药联合首选RAAS抑制剂（ACEI/ARB）+ CCB或利尿剂。中国高血压指南2018修订版ARB+噻嗪类利尿剂的SPC是我国临床主要推荐应用的优化复方制剂之一，两者合用有协同作用，有利于改善降压效果。高血压合理用药指南第二版ARB+利尿剂组合的优势人群：适用于高盐负荷及盐敏感性高血压、老年和高龄老年高血压、高血压合并糖尿病、高血压合并心功能不全、高血压合并肥胖等患者。替米沙坦氢氯噻嗪是该类药物的经典代表之一，它是由ARB类药物替米沙坦+噻嗪型利尿剂氢氯噻嗪所组成的SPC。“超越降压，全面保护”，替米沙坦氢氯噻嗪不但能够24小时强效、平稳、长效降压，并且还具有保护心、脑、肾等靶器官的额外获益。招商电话：0512-66060668-8338扫二维码，获取全国招商联系方式参考文献：1.中国高血压防治指南2018年修订版.心脑血管病防治,2019,19(1):1-44.2.2023 ESH Guidelines for the management of arterial hypertension. Journal of Hypertension, June 21, 2023.3.高血压合理用药指南（第二版）.中国医学前沿杂志,2017,9(7):28-126.声明：此篇文章受众仅为医药、医疗等健康产业专业伙伴，仅供医学药学专业人士使用，不针对普通消费大众。